Pharmacotherapy for Hoarding Disorder: How did the Picture Change since its Excision from OCD?

(E-pub Ahead of Print)

Author(s): Daria Piacentino*, Massimo Pasquini , Gabriele Sani, Chiara Chetoni, Simone Cappelletti, Georgios D. Kotzalidis.

Journal Name: Current Neuropharmacology

Submit Manuscript
Submit Proposal

Abstract:

This brief review deals with the various issues that contributed to the creation of the new Diagnostic and Statistical Manual condition of hoarding disorder (HD) and attempts at reviewing its pharmacotherapy. It appears that after the newly founded diagnosis appeared in the literature as an autonomous entity, distinct from obsessive-compulsive disorder, drug trials are not being conducted and the disorder is left in the hands of psychotherapists, who on their part, report fair results in some core dimensions of HD. The few trials on HD specifically regard the serotonin-noradrenaline reuptake inhibitor venlafaxine, and, possibly due to the suggestion of a common biological background of HD with attention deficit/hyperactivity disorder, the psychostimulant methylphenidate and the noradrenaline reuptake inhibitor atomoxetine. For all these drugs, positive results have been reported, but the evidence level of these studies is low, due to small samples and non-blind designs. Regretfully, there are currently no future studies aiming at seriously testing drugs in HD.

Keywords: Hoarding disorder, Obsessive-compulsive disorder, Drug Treatment, Cognitive-behavioural therapy, Atomoxetine, Methylphenidate, Venlafaxine

Rights & PermissionsPrintExport Cite as


Article Details

(E-pub Ahead of Print)
DOI: 10.2174/1570159X17666190124153048
Price: $95